Small Cell Carcinoma of the Prostate (SCPC):

Complete Response to
Cyclophosphamide, Doxorubicin ane Etopocide (CDE)

Small cell carcinoma of the prostate (SCPC) is an aggressive tumor with a tendency to metastasize early. The prognosis for patients with this histologic variant of prostate cancer is poor. There is no standard chemotherapy regimen for SCPC. We report a 77 year old patient with stage D-2 SCPC who achieved a CR with Cyclophosphamide, Doxorubicin and Etoposide (CDE). The regimen involved Cyclophosphamide at a dose of 50 mg po bid x 14 days, Etoposide at 50 po qd x 21 days and weekly Doxorubicin at 20 mg iv q wk. Courses were repeated q 29 days. Baseline tumor markers included serum neuron-specific enolase (NSE) of 119 [nl to 12.5], and an LDH of 932. After 1 cycle of CDE the NSE and LDH returned to normal with values of 11.7 and 176 respectively. After 4 cycles of therapy a PET total body scan was normal. The patient is off all therapy after 6 cycles and is now 7 months in complete remission. The regimen was well-tolerated with moderate leukopenia. Alopecia was total. This regimen should be considered in patients with SCPC. A central repository to register patients with this rare variant and to evaluate treatment response to CDE and other protocols is encouraged.

 

Prostate Cancer Research Institute (PCRI)

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.